Recruiting PHASE3 INTERVENTIONAL 2-arm NCT06123754

Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC

A Randomized, Controlled, Double-blind, Multicenter Phase III Clinical Study of Envafolimab Plus Platinum-based Doublet Chemotherapy Versus Placebo Plus Platinum-based Doublet Chemotherapy in Patients With Non-small Cell Lung Cancer

Sponsor: 3D Medicines (Sichuan) Co., Ltd.

Conditions Non-small Cell Lung Cancer

Interventions Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection

Updated 6 times since 2023 Last updated: May 18, 2025 Started: Nov 17, 2023 Primary completion: Dec 30, 2025 Completion: Sep 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Non-small Cell Lung Cancer, this trial is actively recruiting participants. The trial is conducted by 3D Medicines (Sichuan) Co., Ltd. and has accumulated 6 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE3
Jun 2025 — Sep 2025 [monthly]

Recruiting PHASE3
Sep 2024 — Jun 2025 [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Feb 2024 — Jul 2024 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Dec 2023 — Feb 2024 [monthly]

Not Yet Recruiting PHASE3

First recorded

Nov 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

3D Medicines (Sichuan) Co., Ltd.

Data source: 3D Medicines

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tianjin, China